페그필그라스팀 바이오시밀러 시장 규모, 점유율, 성장 분석 : 제품별, 투여 경로별, 용도별, 유통 경로별, 지역별 - 업계 예측(2026-2033년)

Global Pegfilgrastim Biosimilar Market size was valued at USD 3.52 Billion in 2024 and is poised to grow from USD 3.77 Billion in 2025 to USD 6.52 Billion by 2033, growing at a CAGR of 7.1% during the forecast period (2026-2033).

The global pegfilgrastim biosimilar market is experiencing significant growth, driven by the need to lower chemotherapy-related neutropenia treatment costs. The high price of the original pegfilgrastim product has made it unaffordable for many healthcare systems, prompting a shift towards more cost-effective biosimilars. Advances in cell-culture technology and regulatory processes have accelerated this sector's development, allowing early entrants to demonstrate similar efficacy to the original drug. This transition is further incentivized by the potential savings hospitals can achieve, which can then be redirected to innovative therapies like immunotherapies. As healthcare providers increasingly adopt biosimilars, the competitive landscape fosters investments in manufacturing and encourages regulatory bodies to facilitate quicker approvals, enhancing market accessibility and improving patient outcomes globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pegfilgrastim Biosimilar market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pegfilgrastim Biosimilar Market Segments Analysis

Global pegfilgrastim biosimilar market is segmented by product, administration, application, distribution and region. Based on product, the market is segmented into pegfilgrastim biosimilar and on-body injector versions. Based on administration, the market is segmented into pre-filled syringe and on-body injector. Based on application, the market is segmented into chemotherapy-induced neutropenia (CIN) and severe chronic neutropenia. Based on distribution, the market is segmented into hospital pharmacies, specialty pharmacies and direct to patients. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pegfilgrastim Biosimilar Market

Increasing financial pressures associated with managing chemotherapy-induced neutropenia have led hospitals to seek more affordable supportive treatments. Pegfilgrastim biosimilars offer similar efficacy to the reference product but at a reduced cost, enabling greater patient access to essential therapy. These alternatives align with budgetary constraints faced by institutions and support value-based care models that encourage their adoption. As a result, healthcare systems are focusing on acquiring cost-effective biologics, which boosts market expansion and creates ongoing growth prospects for biosimilar manufacturers globally. This shift also allows pharmaceutical companies to broaden their product ranges and enhances their investment in biosimilar development and regulatory processes, fostering a dynamic market landscape.

Restraints in the Global Pegfilgrastim Biosimilar Market

The global pegfilgrastim biosimilar market faces significant restraints due to the stringent requirements imposed by regulatory authorities for establishing biosimilarity. These requirements necessitate extensive comparative clinical data, which lead to prolonged review periods and heightened scrutiny. Manufacturers must allocate considerable resources to conduct head-to-head trials, perform analytical characterization, and develop pharmacovigilance plans, all of which increase development costs and delay market entry. Such procedural complexities often discourage smaller companies from participating in the market, resulting in a limited number of approved biosimilars and consequently reducing competitive dynamics. Additionally, the need for separate submissions to meet various regional regulations further extends timelines and hampers rapid market penetration.

Market Trends of the Global Pegfilgrastim Biosimilar Market

The global Pegfilgrastim biosimilar market is witnessing a significant upward trend, characterized by the expanding adoption of these biosimilars in diverse oncology indications. Oncologists are increasingly confident in the safety and efficacy of pegfilgrastim biosimilars, leading to their integration into standard chemotherapy protocols for both solid tumors and hematologic malignancies. This trend is further bolstered by hospitals' efforts to optimize inventory management and minimize treatment delays, prompting the establishment of biosimilar-first policies by guideline committees. As a result, the market experiences enhanced penetration and accessibility, fostering improved therapeutic continuity and broadening patient access to critical cancer care worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Pegfilgrastim Biosimilar Market Size by Product & CAGR (2026-2033)

• Market Overview
• Pegfilgrastim Biosimilar (Reference: Neulasta)
• On-Body Injector Versions

Global Pegfilgrastim Biosimilar Market Size by Administration & CAGR (2026-2033)

• Market Overview
• Pre-filled Syringe
• On-Body Injector

Global Pegfilgrastim Biosimilar Market Size by Application & CAGR (2026-2033)

• Market Overview
• Chemotherapy-Induced Neutropenia (CIN)
• Severe Chronic Neutropenia

Global Pegfilgrastim Biosimilar Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies
• Direct to Patients

Global Pegfilgrastim Biosimilar Market Size & CAGR (2026-2033)

• North America (Product, Administration, Application, Distribution)
  • US
  • Canada
• Europe (Product, Administration, Application, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Administration, Application, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Administration, Application, Distribution)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Administration, Application, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen Inc. (Neulasta - originator)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences (Udenyca)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan/Viatris (Fulphila)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (Novartis) - Ziextenzo
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (Nyvepria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis (Fylnetra)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apotex
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hospira (Pfizer)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla BioTec
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reliance Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (Eugia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations